Free Cash Flow (FCF): $1.09B
The free cash flow (FCF) is $1.09B. It is above its 12-month average by 28.34% ($848.93M).
EW Free Cash Flow (FCF)
Reported quarterly free cash flow; no daily interpolation.
EW Quarterly Free Cash Flow Growth (YoY)
Free Cash Flow growth vs the same quarter one year earlier, last 20 quarters.
EW Average Free Cash Flow (FCF) Chart
EW Current vs Average Free Cash Flow (FCF) Chart
EW Free Cash Flow (FCF) Metrics
FREE CASH FLOW (FCF)
$1.09B
FREE CASH FLOW (FCF) AVG TTM
$848.93M
FREE CASH FLOW (FCF) AVG 3Y
$722.96M
FREE CASH FLOW (FCF) AVG 5Y
$877.66M
FREE CASH FLOW (FCF) AVG 10Y
$780.45M
FREE CASH FLOW (FCF) AVG 15Y
$664.58M
FREE CASH FLOW (FCF) AVG 20Y
$531.92M
CURRENT VS TTM AVG
+28.34%
CURRENT VS 3Y AVG
+50.70%
CURRENT VS 5Y AVG
+24.14%
CURRENT VS 10Y AVG
+39.60%
CURRENT VS 15Y AVG
+63.94%
CURRENT VS 20Y AVG
+104.82%
FCF Analysis
Free Cash Flow (TTM)
$1.09B
FCF Yield
2.07%
Price/FCF
48.4
Formula: FCF = Operating Cash Flow - Capital Expenditures
Why FCF matters:
- Shows actual cash available (not accounting earnings)
- Funds dividends, buybacks, and debt reduction
- Less susceptible to accounting manipulation than net income
- Key metric for DCF valuation models
Free Cash Flow (FCF) Formula & Definition
Free Cash Flow represents the cash a company generates after accounting for capital expenditures. It's the cash available for dividends, buybacks, debt reduction, or reinvestment.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Free Cash Flow (FCF) FAQ
- What is the free cash flow (FCF) for Edwards Lifesciences Corporation (EW)?
- The free cash flow (FCF) for EW stock is $1.09B.
- What is the TTM average free cash flow (FCF) for Edwards Lifesciences Corporation (EW)?
- The TTM average free cash flow (FCF) for EW stock is $848.93M.
- What is the 3Y average free cash flow (FCF) for Edwards Lifesciences Corporation (EW)?
- The 3Y average free cash flow (FCF) for EW stock is $722.96M.
- What is the 5Y average free cash flow (FCF) for Edwards Lifesciences Corporation (EW)?
- The 5Y average free cash flow (FCF) for EW stock is $877.66M.
- What is the 10Y average free cash flow (FCF) for Edwards Lifesciences Corporation (EW)?
- The 10Y average free cash flow (FCF) for EW stock is $780.45M.
- What is the 15Y average free cash flow (FCF) for Edwards Lifesciences Corporation (EW)?
- The 15Y average free cash flow (FCF) for EW stock is $664.58M.
- What is the 20Y average free cash flow (FCF) for Edwards Lifesciences Corporation (EW)?
- The 20Y average free cash flow (FCF) for EW stock is $531.92M.
EW Free Cash Flow (FCF) History
| DATE | FREE CASH FLOW (FCF) |
|---|---|
| 2026-03-31 | $1.09B |
| 2025-09-30 | $804.20M |
| 2025-03-31 | $653.10M |
| 2024-09-30 | $502.20M |
| 2024-03-31 | $238.10M |
| 2023-09-30 | $788.20M |
| 2023-03-31 | $985.40M |
| 2022-09-30 | $1.04B |
| 2022-03-31 | $1.43B |
| 2021-09-30 | $1.41B |
| 2021-03-31 | $716.70M |
| 2020-09-30 | $688.40M |
| 2020-03-31 | $1.08B |
| 2019-09-30 | $805.50M |
| 2019-03-31 | $522.50M |
| 2018-09-30 | $764.70M |
| 2018-03-31 | $820.60M |
| 2017-09-30 | $651.10M |
| 2017-03-31 | $517.30M |
| 2016-09-30 | $411.60M |
| 2016-03-31 | $470.10M |
| 2015-09-30 | $428.60M |
| 2015-03-31 | $856.50M |
| 2014-09-30 | $971.40M |
| 2014-03-31 | $422.90M |
| 2013-09-30 | $342.50M |
| 2013-03-31 | $359.10M |
| 2012-09-30 | $280.90M |
| 2012-03-31 | $174.50M |
| 2011-09-30 | $190.80M |
| 2011-03-31 | $185.30M |
| 2010-09-30 | $158.30M |
| 2010-03-31 | $152.20M |
| 2009-09-30 | $94.90M |
| 2009-03-31 | $7.30M |
| 2008-09-30 | $97.90M |
| 2008-03-31 | $146.00M |
| 2007-09-30 | $141.80M |
| 2007-03-31 | $140.90M |
| 2006-09-30 | $141.20M |
| 2006-03-31 | $126.40M |
| 2005-09-30 | $97.10M |
| 2005-03-31 | $122.90M |
| 2004-09-30 | $163.50M |
| 2004-03-31 | $130.90M |
| 2003-09-30 | $59.20M |
| 2003-03-31 | $72.00M |
Related Metrics
About Edwards Lifesciences Corporation
Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United States, Europe, Japan, and various international territories, the company offers a comprehensive suite of solutions. Their structural heart disease portfolio encompasses transcatheter heart valve replacement systems designed for minimally invasive procedures, as well as transcatheter repair and replacement options specifically targeting mitral and tricuspid valve pathologies, exemplified by their PASCAL and Cardioband systems. Additionally, they provide advanced surgical structural heart solutions, including the INSPIRIS aortic surgical valve, the KONECT RESILIA pre-assembled aortic tissue valved conduit for complex valve, root, and ascending aorta replacements, and the HARPOON Beating Heart Mitral Valve Repair System for patients suffering from degenerative mitral regurgitation. In the realm of critical care, Edwards supplies advanced hemodynamic monitoring systems that assess patients' cardiac function and fluid status in both surgical and intensive care environments. This offering also features the Acumen Hypotension Prediction Index software, which provides early alerts to clinicians regarding potential dangerously low blood pressure. The company distributes its products to healthcare providers through a combination of its proprietary sales force and independent distributor networks. Founded in 1958, Edwards Lifesciences Corporation maintains its headquarters in Irvine, California.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Bernard J. Zovighian